Managing CAR-T Cell Therapy in the Real World | Yi Lin, MD, PhD | IMS 2023

Yi Lin, MD, PhD, offers opinion on anti-BCMA CAR-T cell therapyПодробнее

CAR-T treatment outcomes: MM real-world dataПодробнее

Novel prognosis score for survival in patients with aggressive lymphoma treated with CAR-T therapyПодробнее

Remote management of patients undergoing CAR T-cell therapyПодробнее

Monoclonal Antibodies and CAR T-cell Therapy in Myeloma: Current Status by Yi Lin, MD, PhD | PreviewПодробнее

Real world use of CAR T-cell therapy in multiple myelomaПодробнее

Real-World CAR-T Outcomes, Use of Ide-cel, Cilta-cel for MyelomaПодробнее

Yi Lin, MD, PhD, on how anti-BCMA CAR-T cell therapy fits into the treatment of RRMMПодробнее

CAR T-cell therapy: Mayo Clinic RadioПодробнее

Managing patients that have undergone CAR T-cell therapyПодробнее

Impact of bridging therapy on the outcomes of patients with R/R myeloma treated with ide-celПодробнее

CARTITUDE-1 final results: cilta-cel in heavily pretreated patients with R/R myelomaПодробнее

Panel Discusses Novel BCMA-Targeted CAR-T Therapies in the Myeloma PipelineПодробнее

CAR-T cell therapy: current applications and how to improve treatment strategies in the futureПодробнее

Panelists Discuss Access to CAR-T for Patients with MyelomaПодробнее

Challenges in access to commercial CAR-T therapies in multiple myelomaПодробнее

Understanding how patients relapse from CAR T-cell therapyПодробнее

Prognostic value of early bone marrow and PET MRD assessment in CAR-T therapy for multiple myelomaПодробнее